Barclays initiated coverage of Bruker with an Overweight rating and $75 price target The company’s acquisitions over the past two years has reshaped the portfolio around a more multi-omics approach to research, the analyst tells investors in a research note. The firms says these changes come at a time when customer demand for multi-omics technologies and applications appear to be inflecting. Researchers are moving beyond just looking at genomics and now want a toolkit enabling broader analyses into how proteomics, epigenomics, genomics, and other omics, contends Barclays.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker initiated with an Overweight at Barclays
- Bruker acquires Dynamic Biosensors, terms undisclosed
- Bruker downgraded to Peer Perform from Outperform at Wolfe Research
- Foot Locker trips after earnings, Kohl’s posts Q2 beat: Morning Buzz
- Illumina upgraded, Fiserv initiated: Wall Street’s top analyst calls